Thromboxane amplification

Thromboxane B2 is the stable inactive metabolite of thromboxane A2, a COX-1-generated eicosanoid that amplifies platelet recruitment and aggregation.

Arachidonic acid elevation drives thromboxane-A2 generation and eicosanoid-mediated platelet aggregation and inflammation in acute MI.

COX-2 catalyzes thromboxane-A2 and prostacyclin synthesis, driving platelet activation and inflammation in Type 1 MI.

COX-1 generates thromboxane-A2, which amplifies platelet recruitment and aggregation during coronary thrombosis.

Thromboxane A2 amplifies platelet activation and aggregation through COX-1 pathway, driving thrombus formation and coronary occlusion.

Cyclooxygenase-1 catalyzes arachidonic acid conversion to thromboxane-A2, driving platelet recruitment and coronary thrombosis.

Stable metabolite of thromboxane-A2 that quantifies COX-1-dependent platelet activation amplifying thrombosis.

11-dehydrothromboxane B2 is the stable metabolite of thromboxane A2, marking COX-1-driven platelet activation and recruitment.

11-dehydroTxB2 is the stable urinary metabolite of thromboxane-A2, quantifying COX-1-driven platelet amplification in coronary thrombosis.

2,3-dinor-thromboxane B2 is a urinary metabolite reflecting systemic thromboxane-A2 production, a COX-1-dependent amplifier of platelet recruitment and aggregat

C20:4 (arachidonic acid) is the precursor for thromboxane-A2 and inflammatory mediator synthesis amplifying thrombotic and inflammatory responses in MI.

DGLA is an antithrombotic lipid mediator that suppresses platelet recruitment and thromboxane amplification.

PTGDR regulates prostaglandin-mediated signaling in platelets; smoking-associated variants alter thrombotic susceptibility in AMI.

TPRA2 is the thromboxane-A2 G-protein-coupled receptor on platelets, whose signaling amplifies platelet recruitment and aggregation in coronary thrombosis.

TBXAS1 encodes COX-1 product thromboxane synthase, driving platelet activation and arterial thrombosis in acute MI.